ES2255157T3 - Reactivo de tiempo de protrombina basado en el factor tisular recombinante de conejo. - Google Patents

Reactivo de tiempo de protrombina basado en el factor tisular recombinante de conejo.

Info

Publication number: ES2255157T3
Authority: ES; Spain
Prior art keywords: tissue factor; protein; rabbit; reagent; recombinant
Prior art date: 1997-04-23
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Expired - Lifetime

Application number

ES98918354T

Other languages

English (en)

Spanish (es)

Inventor

Cheryl Brucato

Cynthia Birr

Paul Bruguera

Juan Ruiz

Demetrio Sanchez-Martinez

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Instrumentation Laboratory SpA

Original Assignee

Instrumentation Laboratory SpA

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1997-04-23

Filing date

1998-04-22

Publication date

2006-06-16

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=21932957&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2255157(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

1998-04-22 Application filed by Instrumentation Laboratory SpA filed Critical Instrumentation Laboratory SpA

2006-06-16 Application granted granted Critical

2006-06-16 Publication of ES2255157T3 publication Critical patent/ES2255157T3/es

2018-04-22 Anticipated expiration legal-status Critical

Status Expired - Lifetime legal-status Critical Current

Links

239000003153 chemical reaction reagent Substances 0.000 title claims abstract description 100
241000283973 Oryctolagus cuniculus Species 0.000 title claims abstract description 81
108010000499 Thromboplastin Proteins 0.000 claims abstract description 115
102000002262 Thromboplastin Human genes 0.000 claims abstract description 114
238000000034 method Methods 0.000 claims abstract description 42
108010094028 Prothrombin Proteins 0.000 claims abstract description 32
102100027378 Prothrombin Human genes 0.000 claims abstract description 32
238000002360 preparation method Methods 0.000 claims abstract description 32
229940039716 prothrombin Drugs 0.000 claims abstract description 32
108010049003 Fibrinogen Proteins 0.000 claims abstract description 23
102000008946 Fibrinogen Human genes 0.000 claims abstract description 23
229940012952 fibrinogen Drugs 0.000 claims abstract description 23
239000007788 liquid Substances 0.000 claims abstract description 8
108090000623 proteins and genes Proteins 0.000 claims description 63
102000004169 proteins and genes Human genes 0.000 claims description 55
150000003904 phospholipids Chemical class 0.000 claims description 45
239000000203 mixture Substances 0.000 claims description 40
230000015271 coagulation Effects 0.000 claims description 18
238000005345 coagulation Methods 0.000 claims description 18
150000002632 lipids Chemical class 0.000 claims description 17
239000004094 surface-active agent Substances 0.000 claims description 16
230000004576 lipid-binding Effects 0.000 claims description 13
239000003550 marker Substances 0.000 claims description 13
239000000243 solution Substances 0.000 claims description 13
TZCPCKNHXULUIY-RGULYWFUSA-N 1,2-distearoyl-sn-glycero-3-phosphoserine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCCCC TZCPCKNHXULUIY-RGULYWFUSA-N 0.000 claims description 11
ZWZWYGMENQVNFU-UHFFFAOYSA-N Glycerophosphorylserin Natural products OC(=O)C(N)COP(O)(=O)OCC(O)CO ZWZWYGMENQVNFU-UHFFFAOYSA-N 0.000 claims description 11
210000004899 c-terminal region Anatomy 0.000 claims description 11
229940024606 amino acid Drugs 0.000 claims description 10
150000001413 amino acids Chemical group 0.000 claims description 10
WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 claims description 10
239000000725 suspension Substances 0.000 claims description 8
239000007853 buffer solution Substances 0.000 claims description 7
239000006185 dispersion Substances 0.000 claims description 7
JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 claims description 6
BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 claims description 6
229910001424 calcium ion Inorganic materials 0.000 claims description 6
239000012537 formulation buffer Substances 0.000 claims description 6
HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims description 6
238000002156 mixing Methods 0.000 claims description 6
108010093488 His-His-His-His-His-His Proteins 0.000 claims description 5
101000635804 Homo sapiens Tissue factor Proteins 0.000 claims description 5
102100023804 Coagulation factor VII Human genes 0.000 claims description 4
108010023321 Factor VII Proteins 0.000 claims description 4
108010063628 acarboxyprothrombin Proteins 0.000 claims description 4
230000003834 intracellular effect Effects 0.000 claims description 4
108010054265 Factor VIIa Proteins 0.000 claims description 2
229940012413 factor vii Drugs 0.000 claims description 2
229940012414 factor viia Drugs 0.000 claims description 2
-1 histidine amino acids Chemical class 0.000 claims description 2
230000001939 inductive effect Effects 0.000 claims description 2
101000635808 Bos taurus Tissue factor Proteins 0.000 claims 1
230000008030 elimination Effects 0.000 claims 1
238000003379 elimination reaction Methods 0.000 claims 1
235000018102 proteins Nutrition 0.000 description 44
239000000872 buffer Substances 0.000 description 18
238000009472 formulation Methods 0.000 description 17
PGOHTUIFYSHAQG-LJSDBVFPSA-N (2S)-6-amino-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-1-[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-1-[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-4-methylsulfanylbutanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-5-carbamimidamidopentanoyl]amino]propanoyl]pyrrolidine-2-carbonyl]amino]-3-methylbutanoyl]amino]-4-methylpentanoyl]amino]-4-methylpentanoyl]amino]acetyl]amino]-3-hydroxypropanoyl]amino]-4-methylpentanoyl]amino]-3-sulfanylpropanoyl]amino]-4-methylsulfanylbutanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-hydroxybutanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-3-hydroxypropanoyl]amino]-3-hydroxypropanoyl]amino]-3-(1H-imidazol-5-yl)propanoyl]amino]-4-methylpentanoyl]amino]-3-hydroxybutanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-5-carbamimidamidopentanoyl]amino]-5-oxopentanoyl]amino]-3-hydroxybutanoyl]amino]-3-hydroxypropanoyl]amino]-3-carboxypropanoyl]amino]-3-hydroxypropanoyl]amino]-5-oxopentanoyl]amino]-5-oxopentanoyl]amino]-3-phenylpropanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-methylbutanoyl]amino]-4-methylpentanoyl]amino]-4-oxobutanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-4-carboxybutanoyl]amino]-5-oxopentanoyl]amino]hexanoic acid Chemical compound CSCC[C@H](N)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCCN)C(O)=O PGOHTUIFYSHAQG-LJSDBVFPSA-N 0.000 description 12
230000000694 effects Effects 0.000 description 12
238000012360 testing method Methods 0.000 description 12
239000003146 anticoagulant agent Substances 0.000 description 11
230000035945 sensitivity Effects 0.000 description 11
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 10
238000002560 therapeutic procedure Methods 0.000 description 10
235000001014 amino acid Nutrition 0.000 description 9
229920000669 heparin Polymers 0.000 description 9
230000027455 binding Effects 0.000 description 7
210000004027 cell Anatomy 0.000 description 7
239000000047 product Substances 0.000 description 7
238000000746 purification Methods 0.000 description 7
DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 6
PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 6
230000004913 activation Effects 0.000 description 6
210000004556 brain Anatomy 0.000 description 6
MYSWGUAQZAJSOK-UHFFFAOYSA-N ciprofloxacin Chemical compound C12=CC(N3CCNCC3)=C(F)C=C2C(=O)C(C(=O)O)=CN1C1CC1 MYSWGUAQZAJSOK-UHFFFAOYSA-N 0.000 description 6
230000006870 function Effects 0.000 description 6
235000014304 histidine Nutrition 0.000 description 6
HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 5
229940127219 anticoagulant drug Drugs 0.000 description 5
239000004599 antimicrobial Substances 0.000 description 5
239000012634 fragment Substances 0.000 description 5
229960002897 heparin Drugs 0.000 description 5
239000002502 liposome Substances 0.000 description 5
229910052751 metal Inorganic materials 0.000 description 5
239000002184 metal Substances 0.000 description 5
239000011780 sodium chloride Substances 0.000 description 5
102000015081 Blood Coagulation Factors Human genes 0.000 description 4
108010039209 Blood Coagulation Factors Proteins 0.000 description 4
UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 4
102000009123 Fibrin Human genes 0.000 description 4
108010073385 Fibrin Proteins 0.000 description 4
BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 4
229920000209 Hexadimethrine bromide Polymers 0.000 description 4
240000004808 Saccharomyces cerevisiae Species 0.000 description 4
229930003448 Vitamin K Natural products 0.000 description 4
125000003275 alpha amino acid group Chemical group 0.000 description 4
239000003114 blood coagulation factor Substances 0.000 description 4
230000015556 catabolic process Effects 0.000 description 4
239000013522 chelant Substances 0.000 description 4
238000006243 chemical reaction Methods 0.000 description 4
238000006731 degradation reaction Methods 0.000 description 4
XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 4
229950003499 fibrin Drugs 0.000 description 4
230000014509 gene expression Effects 0.000 description 4
239000002607 heparin antagonist Substances 0.000 description 4
125000000487 histidyl group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C([H])=N1 0.000 description 4
230000001965 increasing effect Effects 0.000 description 4
239000003112 inhibitor Substances 0.000 description 4
210000004185 liver Anatomy 0.000 description 4
229940127216 oral anticoagulant drug Drugs 0.000 description 4
SHUZOJHMOBOZST-UHFFFAOYSA-N phylloquinone Natural products CC(C)CCCCC(C)CCC(C)CCCC(=CCC1=C(C)C(=O)c2ccccc2C1=O)C SHUZOJHMOBOZST-UHFFFAOYSA-N 0.000 description 4
239000003381 stabilizer Substances 0.000 description 4
239000013598 vector Substances 0.000 description 4
235000019168 vitamin K Nutrition 0.000 description 4
239000011712 vitamin K Substances 0.000 description 4
150000003721 vitamin K derivatives Chemical class 0.000 description 4
229940046010 vitamin k Drugs 0.000 description 4
108091003079 Bovine Serum Albumin Proteins 0.000 description 3
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 3
239000004471 Glycine Substances 0.000 description 3
102000003886 Glycoproteins Human genes 0.000 description 3
108090000288 Glycoproteins Proteins 0.000 description 3
241000235058 Komagataella pastoris Species 0.000 description 3
238000002835 absorbance Methods 0.000 description 3
239000005557 antagonist Substances 0.000 description 3
230000015572 biosynthetic process Effects 0.000 description 3
229940098773 bovine serum albumin Drugs 0.000 description 3
229960005069 calcium Drugs 0.000 description 3
229910052791 calcium Inorganic materials 0.000 description 3
239000011575 calcium Substances 0.000 description 3
230000008859 change Effects 0.000 description 3
229960003405 ciprofloxacin Drugs 0.000 description 3
239000002299 complementary DNA Substances 0.000 description 3
238000013461 design Methods 0.000 description 3
238000001514 detection method Methods 0.000 description 3
238000010353 genetic engineering Methods 0.000 description 3
238000000703 high-speed centrifugation Methods 0.000 description 3
RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
239000004615 ingredient Substances 0.000 description 3
230000000977 initiatory effect Effects 0.000 description 3
208000019423 liver disease Diseases 0.000 description 3
238000004519 manufacturing process Methods 0.000 description 3
229910052759 nickel Inorganic materials 0.000 description 3
239000002736 nonionic surfactant Substances 0.000 description 3
230000037361 pathway Effects 0.000 description 3
239000013612 plasmid Substances 0.000 description 3
238000012216 screening Methods 0.000 description 3
XNRNJIIJLOFJEK-UHFFFAOYSA-N sodium;1-oxidopyridine-2-thione Chemical compound [Na+].[O-]N1C=CC=CC1=S XNRNJIIJLOFJEK-UHFFFAOYSA-N 0.000 description 3
238000012546 transfer Methods 0.000 description 3
PJVWKTKQMONHTI-UHFFFAOYSA-N warfarin Chemical compound OC=1C2=CC=CC=C2OC(=O)C=1C(CC(=O)C)C1=CC=CC=C1 PJVWKTKQMONHTI-UHFFFAOYSA-N 0.000 description 3
210000005253 yeast cell Anatomy 0.000 description 3
241000283690 Bos taurus Species 0.000 description 2
RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 2
229920002307 Dextran Polymers 0.000 description 2
239000002202 Polyethylene glycol Substances 0.000 description 2
102000007056 Recombinant Fusion Proteins Human genes 0.000 description 2
108010008281 Recombinant Fusion Proteins Proteins 0.000 description 2
201000000839 Vitamin K Deficiency Bleeding Diseases 0.000 description 2
206010047634 Vitamin K deficiency Diseases 0.000 description 2
229940118377 Vitamin antagonist Drugs 0.000 description 2
HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 2
230000002159 abnormal effect Effects 0.000 description 2
238000001042 affinity chromatography Methods 0.000 description 2
230000010100 anticoagulation Effects 0.000 description 2
238000000149 argon plasma sintering Methods 0.000 description 2
238000003556 assay Methods 0.000 description 2
239000003139 biocide Substances 0.000 description 2
230000004071 biological effect Effects 0.000 description 2
238000010367 cloning Methods 0.000 description 2
229910017052 cobalt Inorganic materials 0.000 description 2
239000010941 cobalt Substances 0.000 description 2
GUTLYIVDDKVIGB-UHFFFAOYSA-N cobalt atom Chemical compound [Co] GUTLYIVDDKVIGB-UHFFFAOYSA-N 0.000 description 2
229910052802 copper Inorganic materials 0.000 description 2
239000010949 copper Substances 0.000 description 2
230000007812 deficiency Effects 0.000 description 2
238000010790 dilution Methods 0.000 description 2
239000012895 dilution Substances 0.000 description 2
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
239000000284 extract Substances 0.000 description 2
230000006624 extrinsic pathway Effects 0.000 description 2
238000011534 incubation Methods 0.000 description 2
150000002500 ions Chemical class 0.000 description 2
239000012669 liquid formulation Substances 0.000 description 2
206010025135 lupus erythematosus Diseases 0.000 description 2
238000005259 measurement Methods 0.000 description 2
239000000546 pharmaceutical excipient Substances 0.000 description 2
229920001223 polyethylene glycol Polymers 0.000 description 2
235000019260 propionic acid Nutrition 0.000 description 2
239000012264 purified product Substances 0.000 description 2
IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 2
238000005215 recombination Methods 0.000 description 2
230000006798 recombination Effects 0.000 description 2
239000007787 solid Substances 0.000 description 2
208000016794 vitamin K deficiency hemorrhagic disease Diseases 0.000 description 2
229960005080 warfarin Drugs 0.000 description 2
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
229910052725 zinc Inorganic materials 0.000 description 2
239000011701 zinc Substances 0.000 description 2
IHPYMWDTONKSCO-UHFFFAOYSA-N 2,2'-piperazine-1,4-diylbisethanesulfonic acid Chemical group OS(=O)(=O)CCN1CCN(CCS(O)(=O)=O)CC1 IHPYMWDTONKSCO-UHFFFAOYSA-N 0.000 description 1
101150061183 AOX1 gene Proteins 0.000 description 1
102100036826 Aldehyde oxidase Human genes 0.000 description 1
102000014914 Carrier Proteins Human genes 0.000 description 1
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
108090000790 Enzymes Proteins 0.000 description 1
102000004190 Enzymes Human genes 0.000 description 1
108010029144 Factor IIa Proteins 0.000 description 1
244000068988 Glycine max Species 0.000 description 1
235000010469 Glycine max Nutrition 0.000 description 1
101150069554 HIS4 gene Proteins 0.000 description 1
208000031220 Hemophilia Diseases 0.000 description 1
208000009292 Hemophilia A Diseases 0.000 description 1
206010019663 Hepatic failure Diseases 0.000 description 1
101000928314 Homo sapiens Aldehyde oxidase Proteins 0.000 description 1
241001506991 Komagataella phaffii GS115 Species 0.000 description 1
102000018697 Membrane Proteins Human genes 0.000 description 1
108010052285 Membrane Proteins Proteins 0.000 description 1
108700026244 Open Reading Frames Proteins 0.000 description 1
101150023810 PHO1 gene Proteins 0.000 description 1
239000007990 PIPES buffer Substances 0.000 description 1
239000002033 PVDF binder Substances 0.000 description 1
101800004937 Protein C Proteins 0.000 description 1
102000017975 Protein C Human genes 0.000 description 1
229940096437 Protein S Drugs 0.000 description 1
102000029301 Protein S Human genes 0.000 description 1
108010066124 Protein S Proteins 0.000 description 1
108010076504 Protein Sorting Signals Proteins 0.000 description 1
101100271429 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) ATP6 gene Proteins 0.000 description 1
101800001700 Saposin-D Proteins 0.000 description 1
108090000190 Thrombin Proteins 0.000 description 1
239000007983 Tris buffer Substances 0.000 description 1
101100115751 Trypanosoma brucei brucei dnaaf11 gene Proteins 0.000 description 1
125000000539 amino acid group Chemical group 0.000 description 1
AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
229960000723 ampicillin Drugs 0.000 description 1
238000004458 analytical method Methods 0.000 description 1
239000003698 antivitamin K Substances 0.000 description 1
239000007864 aqueous solution Substances 0.000 description 1
239000007900 aqueous suspension Substances 0.000 description 1
230000008901 benefit Effects 0.000 description 1
ZYGHJZDHTFUPRJ-UHFFFAOYSA-N benzo-alpha-pyrone Natural products C1=CC=C2OC(=O)C=CC2=C1 ZYGHJZDHTFUPRJ-UHFFFAOYSA-N 0.000 description 1
108091008324 binding proteins Proteins 0.000 description 1
210000000601 blood cell Anatomy 0.000 description 1
230000023555 blood coagulation Effects 0.000 description 1
229940019700 blood coagulation factors Drugs 0.000 description 1
239000006227 byproduct Substances 0.000 description 1
239000001110 calcium chloride Substances 0.000 description 1
229910001628 calcium chloride Inorganic materials 0.000 description 1
239000004227 calcium gluconate Substances 0.000 description 1
235000013927 calcium gluconate Nutrition 0.000 description 1
229960004494 calcium gluconate Drugs 0.000 description 1
159000000007 calcium salts Chemical class 0.000 description 1
NEEHYRZPVYRGPP-UHFFFAOYSA-L calcium;2,3,4,5,6-pentahydroxyhexanoate Chemical compound [Ca+2].OCC(O)C(O)C(O)C(O)C([O-])=O.OCC(O)C(O)C(O)C(O)C([O-])=O NEEHYRZPVYRGPP-UHFFFAOYSA-L 0.000 description 1
150000007942 carboxylates Chemical class 0.000 description 1
238000004113 cell culture Methods 0.000 description 1
238000012512 characterization method Methods 0.000 description 1
229960001231 choline Drugs 0.000 description 1
OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
238000004587 chromatography analysis Methods 0.000 description 1
238000012411 cloning technique Methods 0.000 description 1
230000035602 clotting Effects 0.000 description 1
230000000052 comparative effect Effects 0.000 description 1
239000000356 contaminant Substances 0.000 description 1
229940072645 coumadin Drugs 0.000 description 1
235000001671 coumarin Nutrition 0.000 description 1
150000004775 coumarins Chemical class 0.000 description 1
230000006735 deficit Effects 0.000 description 1
230000001419 dependent effect Effects 0.000 description 1
238000000502 dialysis Methods 0.000 description 1
229960001912 dicoumarol Drugs 0.000 description 1
DOBMPNYZJYQDGZ-UHFFFAOYSA-N dicoumarol Chemical compound C1=CC=CC2=C1OC(=O)C(CC=1C(OC3=CC=CC=C3C=1O)=O)=C2O DOBMPNYZJYQDGZ-UHFFFAOYSA-N 0.000 description 1
HIZKPJUTKKJDGA-UHFFFAOYSA-N dicumarol Natural products O=C1OC2=CC=CC=C2C(=O)C1CC1C(=O)C2=CC=CC=C2OC1=O HIZKPJUTKKJDGA-UHFFFAOYSA-N 0.000 description 1
238000007865 diluting Methods 0.000 description 1
201000010099 disease Diseases 0.000 description 1
208000035475 disorder Diseases 0.000 description 1
229940088598 enzyme Drugs 0.000 description 1
238000000855 fermentation Methods 0.000 description 1
230000004151 fermentation Effects 0.000 description 1
239000000706 filtrate Substances 0.000 description 1
238000001914 filtration Methods 0.000 description 1
230000005714 functional activity Effects 0.000 description 1
238000003208 gene overexpression Methods 0.000 description 1
125000000291 glutamic acid group Chemical group N[C@@H](CCC(O)=O)C(=O)* 0.000 description 1
238000010438 heat treatment Methods 0.000 description 1
150000002411 histidines Chemical class 0.000 description 1
238000000338 in vitro Methods 0.000 description 1
230000005764 inhibitory process Effects 0.000 description 1
230000003993 interaction Effects 0.000 description 1
208000007903 liver failure Diseases 0.000 description 1
231100000835 liver failure Toxicity 0.000 description 1
210000004072 lung Anatomy 0.000 description 1
239000012931 lyophilized formulation Substances 0.000 description 1
239000012139 lysis buffer Substances 0.000 description 1
239000012528 membrane Substances 0.000 description 1
150000002739 metals Chemical class 0.000 description 1
230000004048 modification Effects 0.000 description 1
238000012986 modification Methods 0.000 description 1
WVFLGSMUPMVNTQ-UHFFFAOYSA-N n-(2-hydroxyethyl)-2-[[1-(2-hydroxyethylamino)-2-methyl-1-oxopropan-2-yl]diazenyl]-2-methylpropanamide Chemical compound OCCNC(=O)C(C)(C)N=NC(C)(C)C(=O)NCCO WVFLGSMUPMVNTQ-UHFFFAOYSA-N 0.000 description 1
229930014626 natural product Natural products 0.000 description 1
230000007935 neutral effect Effects 0.000 description 1
230000003287 optical effect Effects 0.000 description 1
239000012071 phase Substances 0.000 description 1
BZQFBWGGLXLEPQ-REOHCLBHSA-N phosphoserine Chemical compound OC(=O)[C@@H](N)COP(O)(O)=O BZQFBWGGLXLEPQ-REOHCLBHSA-N 0.000 description 1
210000002826 placenta Anatomy 0.000 description 1
229920002981 polyvinylidene fluoride Polymers 0.000 description 1
230000004481 post-translational protein modification Effects 0.000 description 1
238000001556 precipitation Methods 0.000 description 1
238000004321 preservation Methods 0.000 description 1
230000008569 process Effects 0.000 description 1
229960000856 protein c Drugs 0.000 description 1
238000001742 protein purification Methods 0.000 description 1
239000012460 protein solution Substances 0.000 description 1
230000002797 proteolythic effect Effects 0.000 description 1
108010014806 prothrombinase complex Proteins 0.000 description 1
230000009257 reactivity Effects 0.000 description 1
230000009467 reduction Effects 0.000 description 1
239000011347 resin Substances 0.000 description 1
229920005989 resin Polymers 0.000 description 1
108091008146 restriction endonucleases Proteins 0.000 description 1
230000000717 retained effect Effects 0.000 description 1
230000001932 seasonal effect Effects 0.000 description 1
238000012163 sequencing technique Methods 0.000 description 1
239000007790 solid phase Substances 0.000 description 1
238000001179 sorption measurement Methods 0.000 description 1
238000003860 storage Methods 0.000 description 1
239000006228 supernatant Substances 0.000 description 1
229960004072 thrombin Drugs 0.000 description 1
102000035160 transmembrane proteins Human genes 0.000 description 1
108091005703 transmembrane proteins Proteins 0.000 description 1
LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
PIEPQKCYPFFYMG-UHFFFAOYSA-N tris acetate Chemical compound CC(O)=O.OCC(N)(CO)CO PIEPQKCYPFFYMG-UHFFFAOYSA-N 0.000 description 1
GPRLSGONYQIRFK-MNYXATJNSA-N triton Chemical compound [3H+] GPRLSGONYQIRFK-MNYXATJNSA-N 0.000 description 1
239000002821 viper venom Substances 0.000 description 1
230000003612 virological effect Effects 0.000 description 1
229940019333 vitamin k antagonists Drugs 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/745—Blood coagulation or fibrinolysis factors
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/56—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving blood clotting factors, e.g. involving thrombin, thromboplastin, fibrinogen
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/86—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood coagulating time or factors, or their receptors
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
- Y10S530/827—Proteins from mammals or birds
- Y10S530/829—Blood
- Y10S530/83—Plasma; serum

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Molecular Biology (AREA)
Hematology (AREA)
Engineering & Computer Science (AREA)
Immunology (AREA)
General Health & Medical Sciences (AREA)
Biochemistry (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Zoology (AREA)
Biophysics (AREA)
Genetics & Genomics (AREA)
Medicinal Chemistry (AREA)
Physics & Mathematics (AREA)
Biomedical Technology (AREA)
Analytical Chemistry (AREA)
Gastroenterology & Hepatology (AREA)
Biotechnology (AREA)
Toxicology (AREA)
Microbiology (AREA)
Wood Science & Technology (AREA)
Urology & Nephrology (AREA)
Cell Biology (AREA)
General Engineering & Computer Science (AREA)
Neurosurgery (AREA)
Bioinformatics & Cheminformatics (AREA)
Food Science & Technology (AREA)
General Physics & Mathematics (AREA)
Pathology (AREA)
Peptides Or Proteins (AREA)
Investigating Or Analysing Biological Materials (AREA)
Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

ES98918354T 1997-04-23 1998-04-22 Reactivo de tiempo de protrombina basado en el factor tisular recombinante de conejo. Expired - Lifetime ES2255157T3 (es)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US4454197P	1997-04-23	1997-04-23
US44541P		1997-04-23

Publications (1)

Publication Number	Publication Date
ES2255157T3 true ES2255157T3 (es)	2006-06-16

Family

ID=21932957

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
ES98918354T Expired - Lifetime ES2255157T3 (es)	1997-04-23	1998-04-22	Reactivo de tiempo de protrombina basado en el factor tisular recombinante de conejo.

Country Status (10)

Country	Link
US (1)	US6100072A (de)
EP (1)	EP1015890B1 (de)
JP (1)	JP3246749B2 (de)
AT (1)	ATE311601T1 (de)
AU (1)	AU7129598A (de)
CA (1)	CA2288058A1 (de)
DE (1)	DE69832628T2 (de)
ES (1)	ES2255157T3 (de)
IL (1)	IL132529A0 (de)
WO (1)	WO1998048283A1 (de)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE19811016A1 (de) *	1998-03-13	1999-09-16	Dade Behring Marburg Gmbh	Gebrauchsfertiges Prothrombinzeitreagenz auf der Basis von rekombinantem Gewebsfaktor
US6733985B1 (en) *	1999-05-19	2004-05-11	International Technidyne Corporation	Preparation of stable liquid and dried synthetic prothrombin time reagents
ATE268477T1 (de) *	1999-09-03	2004-06-15	Roche Diagnostics Corp	Verfahren, reagenz und messkartusche zur bestimmung der gerinnungszeit
US6248353B1 (en) *	1999-12-10	2001-06-19	Dade Behring Inc.	Reconstitution of purified membrane proteins into preformed liposomes
JP4526152B2 (ja) *	2000-03-08	2010-08-18	シスメックス株式会社	プロトロンビン時間測定試薬
US6645768B1 (en) *	2000-10-27	2003-11-11	Biomerieux, Inc.	Reagent and kit for determining global coagulability and hemostatic potential
US6855509B2 (en) *	2000-12-19	2005-02-15	Instrumentation Laboratory Company	Protein S functional assay and kit therefor
EP1229048A1 (de) *	2001-02-05	2002-08-07	International Reagents Corporation	Thromboplastinreagenz und Verfahren zu dessen Herstellung
US6902909B2 (en) *	2002-07-09	2005-06-07	Synthecon, Inc.	Methods for efficient production of mammalian recombinant proteins
US7358337B2 (en) *	2002-08-16	2008-04-15	International Technidyne Corporation	Assay for low molecular weight heparin
US7049087B2 (en) *	2002-11-05	2006-05-23	Lifescan, Inc.	Method for manufacturing a tissue factor-based prothrombin time reagent
US7476529B2 (en) *	2003-03-11	2009-01-13	Advanced Biocatalytics Corporation	Altering metabolism in biological processes
US8323949B2 (en) *	2003-03-11	2012-12-04	Advanced Biocatalytics Corporation	Altering metabolism in biological processes
CA2525940A1 (en) *	2003-05-16	2004-11-25	National Institute For Biological Standards And Control (Nibsc)	Mixture
US20050221414A1 (en) *	2004-03-31	2005-10-06	Katalin Varadi	Kit for measuring the thrombin generation in a sample of a patient's blood or plasma
EP1626280B1 (de) *	2004-08-12	2007-02-14	Roche Diagnostics GmbH	Verfahren zur Diagnose von Leberfibrose.
US7148067B2 (en) *	2004-08-31	2006-12-12	The Board Of Trustees Of The University Of Illinois	Thromboplastin reagents
US20080260858A1 (en) *	2005-02-16	2008-10-23	The Board Of Trustees Of The University Of Illnois	Universal Procoagulant
EP1869082B1 (de) *	2005-03-04	2011-04-13	The Board Of Trustees Of The University Of Illinois	Modulator von coagulationskaskaden und fibrinolytischen kaskaden
US7932021B2 (en) *	2005-07-28	2011-04-26	American Diagnostica, Inc.	Lupus anticoagulant testing
JP5073270B2 (ja)	2006-11-14	2012-11-14	シスメックス株式会社	凝固検査用試薬及びその製造方法
EP1939218A1 (de) *	2006-12-29	2008-07-02	Thrombotargets Europe, S.L.	Mikrovesikel aus rekombinanter Hefe mit blutstillender Wirkung und Verwendung dafür
GB0701821D0 (en) *	2007-02-01	2007-03-14	Pentapharm Ag	Diagnostic composition and its use in the determination of coagulation characteristics of a test liquid
JP4999613B2 (ja) *	2007-08-31	2012-08-15	シスメックス株式会社	血液凝固測定用試薬及び血液凝固時間測定方法
WO2009046194A2 (en) *	2007-10-05	2009-04-09	The Board Of Trustees Of The University Of Illinois	Fibrin sealant
US20100297257A1 (en) *	2007-11-09	2010-11-25	National Institutes Of Health (Nih), U.S. Dept. Of Health And Human Services (Dhhs)	Anticoagulant antagonist and hemophillia procoagulant
DE102007062323A1 (de) *	2007-12-21	2009-06-25	Siemens Healthcare Diagnostics Products Gmbh	Langzeitstabiles Thromboplastin-Reagenz
RU2426780C2 (ru) *	2008-11-05	2011-08-20	Общество с ограниченной ответственностью "ИННОВАЦИОННЫЙ ЦЕНТР "НОВЫЕ ТЕХНОЛОГИИ И МАТЕРИАЛЫ" ООО "ИЦ Новтехмат"	ЭКСПРЕССИОННАЯ ПЛАЗМИДНАЯ ДНК p6E-tTF, КОДИРУЮЩАЯ ВНЕКЛЕТОЧНЫЙ И ТРАНСМЕМБРАННЫЙ ДОМЕНЫ ТКАНЕВОГО ФАКТОРА ЧЕЛОВЕКА И ШТАММ E.coli BL21[DE3]/p6E-tTF-ПРОДУЦЕНТ РЕКОМБИНАНТНОГО ТКАНЕВОГО ФАКТОРА ЧЕЛОВЕКА
JP2011133396A (ja) *	2009-12-25	2011-07-07	Sysmex Corp	活性化部分トロンボプラスチン時間測定試薬、活性化部分トロンボプラスチン時間測定方法、及び血液凝固抑制物質の有無の判定方法
EP2380905A1 (de) *	2010-04-19	2011-10-26	Thrombotargets Europe, S.L.	Phospholipidangereicherte Vesikel mit Gewebefaktor mit blutstillenden Aktivitäten sowie Verwendungen davon
RU2550027C2 (ru) *	2012-01-01	2015-05-10	Общество с ограниченной ответственностью "Лаборатория медицинской биотехнологии" (ООО "ЛМБТ")	ЭКСПРЕССИОННАЯ ПЛАЗМИДА, СОДЕРЖАЩАЯ ФРАГМЕНТ ДНК, КОДИРУЮЩИЙ МУТЕИН [C245S] ТКАНЕВОГО ФАКТОРА ЧЕЛОВЕКА С НЕОТДЕЛЯЕМЫМ С-КОНЦЕВЫМ ТАГОМ, БАКТЕРИЯ E. coli - ПРОДУЦЕНТ БЕЛКА-ПРЕДШЕСТВЕННИКА МУТЕИНА [C245S] ТКАНЕВОГО ФАКТОРА ЧЕЛОВЕКА С НЕОТДЕЛЯЕМЫМ С-КОНЦЕВЫМ ТАГОМ, СПОСОБ ПОЛУЧЕНИЯ РЕКОМБИНАНТНОГО МУТЕИНА [C245S] ТКАНЕВОГО ФАКТОРА ЧЕЛОВЕКА С НЕОТДЕЛЯЕМЫМ С-КОНЦЕВЫМ ТАГОМ, РЕКОМБИНАНТНЫЙ МУТЕИН [C245S] ТКАНЕВОГО ФАКТОРА ЧЕЛОВЕКА С НЕОТДЕЛЯЕМЫМ С-КОНЦЕВЫМ ТАГОМ
EA028016B1 (ru) *	2013-06-06	2017-09-29	Общество с ограниченной ответственностью "Гематологическая Корпорация" (ООО "ГемаКор")	Набор для измерения параметров системы гемостаза в образце крови или ее компонентов
CN105424946B (zh) *	2015-07-16	2016-08-24	青岛古高生物科技有限公司	一种含迷迭香酸的凝血酶时间测定试剂
JP6626761B2 (ja)	2016-03-30	2019-12-25	シスメックス株式会社	プロトロンビン時間測定用試薬およびその製造方法
JP6652873B2 (ja) *	2016-03-30	2020-02-26	シスメックス株式会社	プロトロンビン時間測定用試薬、その製造方法およびプロトロンビン時間の測定方法
RU2698206C1 (ru) *	2018-07-02	2019-08-23	Общество с ограниченной ответственностью "Гематологическая Корпорация" (ООО "ГемаКор")	Набор реагентов для диагностики степени нейровоспаления
CN110346559A (zh) *	2019-07-16	2019-10-18	山东艾科达生物科技有限公司	一种冻干型测定pt试剂制备方法
CN110887970B (zh) *	2019-11-29	2023-10-31	北京赛科希德科技股份有限公司	抽提缓冲液、兔脑抽提液、pt检测试剂及pt检测试剂盒

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4755461A (en) *	1986-04-17	1988-07-05	Bio/Data Corporation	Tableted blood plasma microconcentrated thromboplastin coagulation reagent
US5223427A (en) *	1987-03-31	1993-06-29	The Scripps Research Institute	Hybridomas producing monoclonal antibodies reactive with human tissue-factor glycoprotein heavy chain
US5270451A (en) *	1988-11-23	1993-12-14	Baxter Diagnostics Inc.	Extraction method for preparing thromboplastin reagents
WO1990005740A1 (en) *	1988-11-23	1990-05-31	Baxter International Inc.	Improved extraction methods for preparing thromboplastin reagents
US5472850A (en) *	1991-04-10	1995-12-05	Oklahoma Medical Research Foundation	Quantitative clotting assay for activated factor VII
US5298599A (en) *	1988-12-30	1994-03-29	Oklahoma Medical Research Foundation	Expression and purification of recombinant soluble tissue factor
US5314695A (en) *	1990-11-13	1994-05-24	Corvas International, Inc.	Tissue factor based prothrombin time reagent
US5504064A (en) *	1991-04-10	1996-04-02	Oklahoma Medical Research Foundation	Treatment of bleeding with modified tissue factor in combination with an activator of FVII
US5374617A (en) *	1992-05-13	1994-12-20	Oklahoma Medical Research Foundation	Treatment of bleeding with modified tissue factor in combination with FVIIa
US5254350A (en) *	1991-07-22	1993-10-19	Helena Laboratories Corporation	Method of preparing a thromboplastin extract
ES2115679T3 (es) *	1991-10-04	1998-07-01	Dade Behring Inc	Preparacion de reactivos de tiempo de protrombina a partir de factor de tejido humano recombinante y de fosfolipidos sinteticos y naturales purificados.
US5358853A (en) *	1992-08-03	1994-10-25	Akzo Av	Liquid thromboplastin reagent
US5502651A (en) *	1994-05-02	1996-03-26	Jackson; R. David	Potentiophotometric fibrinogen determination
US5418141A (en) *	1994-05-06	1995-05-23	Avocet Medical, Inc.	Test articles for performing dry reagent prothrombin time assays

1998
- 1998-04-22 DE DE69832628T patent/DE69832628T2/de not_active Expired - Fee Related
- 1998-04-22 WO PCT/US1998/007769 patent/WO1998048283A1/en not_active Ceased
- 1998-04-22 CA CA002288058A patent/CA2288058A1/en not_active Abandoned
- 1998-04-22 US US09/064,378 patent/US6100072A/en not_active Expired - Lifetime
- 1998-04-22 IL IL13252998A patent/IL132529A0/xx unknown
- 1998-04-22 ES ES98918354T patent/ES2255157T3/es not_active Expired - Lifetime
- 1998-04-22 EP EP98918354A patent/EP1015890B1/de not_active Revoked
- 1998-04-22 AT AT98918354T patent/ATE311601T1/de not_active IP Right Cessation
- 1998-04-22 JP JP54618598A patent/JP3246749B2/ja not_active Expired - Fee Related
- 1998-04-22 AU AU71295/98A patent/AU7129598A/en not_active Abandoned

Also Published As

Publication number	Publication date
ATE311601T1 (de)	2005-12-15
CA2288058A1 (en)	1998-10-29
IL132529A0 (en)	2001-03-19
EP1015890B1 (de)	2005-11-30
US6100072A (en)	2000-08-08
AU7129598A (en)	1998-11-13
JP3246749B2 (ja)	2002-01-15
WO1998048283A1 (en)	1998-10-29
JPH11514101A (ja)	1999-11-30
DE69832628D1 (de)	2006-01-05
EP1015890A1 (de)	2000-07-05
DE69832628T2 (de)	2006-09-07

Publication	Publication Date	Title
ES2255157T3 (es)	2006-06-16	Reactivo de tiempo de protrombina basado en el factor tisular recombinante de conejo.
JP3416778B2 (ja)	2003-06-16	組換えヒト組織因子及び精製された天然及び合成のリン脂質からのプロトロンビン時間試薬の製造
ES2363307T3 (es)	2011-07-29	Polipéptidos de factor viia mofificados.
JP3047120B2 (ja)	2000-05-29	活性化因子ｖｉｉに関する定量的凝血検定
UA75064C2 (en)	2006-03-15	Modified porcine factor viii and its therapeutic use
Gillis et al.	1997	γ‐Carboxyglutamic acids 36 and 40 do not contribute to human factor IX function
CA2802072A1 (en)	2011-12-22	Treatment of coagulopathy with hyperfibrinolysis
JPH08506181A (ja)	1996-07-02	新規抗凝固性補助因子活性
US7148067B2 (en)	2006-12-12	Thromboplastin reagents
KR101154246B1 (ko)	2012-06-13	활성화 혼합물
ES2328453T3 (es)	2009-11-13	Ensayo funcional de la proteina s.
US20040126856A1 (en)	2004-07-01	Factor ixa: factor Vllla interaction and methods therefor
US20120178693A1 (en)	2012-07-12	Cofactors for Thrombin Activation of Factor VII and Uses Thereof
US20140256640A1 (en)	2014-09-11	Treatment of coagulopathy with hyperfibrinolysis
Sridhara et al.	1993	The direct binding of human factor VII in plasma to recombinant human tissue factor
Fiona et al.	1993	Factor VIII: structure, function and analysis
Morrissey	1999	Activated factor VII
US20150005238A1 (en)	2015-01-01	Treatment of coagulopathy with hyperfibrinolysis
McIntosh	2005	Investigations of the thrombin generation test for the measurement of factor VIII
WO2002059268A2 (en)	2002-08-01	Factor ixa: factor viiia interaction and methods therefor
Williams	1989	Assessment of the interrelationship of the biological activities detected by botrocetin and ristocetin on von Willebrand's factor from normals and patients with von Willebrand's disease
Lapan	1998	Identification and characterization of the FX interactive site on the FVIII cofactor protein